In vivo studies of transdermal drug delivery systems (TDDS) encompass a comprehensive range of tests designed to evaluate the safety and tolerability of these formulations in living organisms. Patch testing, a cornerstone of these studies, involves applying the TDDS to the skin of animals and humans under controlled condi­tions. This method allows researchers to observe and quantify any local reactions, such as erythema, edema, or other signs of irrita­tion. The standardization of these protocols, particularly through the OECD Test Guidelines, ensures that the results are reproduc­ible and comparable across different laboratories and regulator y jurisdictions. Acute irritation tests typically involve short-term exposure to TDDS, whereas cumulative irritation studies assess the effects of repeated applications over an extended period, mim­icking real-world usage patterns. Sensitization studies, such as the local lymph node assay (LLNA) in animals or the human repeated insult patch test (HRIPT), assess the potential of TDDS compo­nents to induce allergic contact dermatitis.

Specific quality control measures for TDDS include rigorous testing of drug substance purity, uniformity of drug distribution within the system, and stability of the formulation over time. Manufacturers are required to implement robust analytical meth­ods to assess critical quality attributes, such as drug release kinetics, adhesive properties, and moisture content. In-process controls are essential for monitoring and maintaining consistency throughout the manufacturing process.

Phase I studies focused on initial safety assessments and phar­macokinetic profiling. These trials often include dermal safety stud­ies to evaluate skin irritation and sensitization potential. Adhesion performance was also assessed during early clinical development.